Clinical Trial Update: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of CFT8634 in SMARCB1-perturbed cancers, including Synovial Sarcoma and SMARCB1-null tumors, has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• CFT8634

Snippet

Sponsor: C4 Therapeutics, Inc. | Conditions: Synovial Sarcoma, Soft Tissue Sarcoma | Phase 1 | Status: TERMINATED